Helicobacter Pylori Infection
Conditions
Brief summary
This randomized controlled clinical trial will compare the eradication efficacy of bismuth quadruple therapy containing clarithromycin+metronidazole, clarithromycin+levofloxacin, or metronidazole+levofloxacin for Helicobacter pylori first-line treatment in penicillin-allergic patients. The completion of this trial will expand new therapy for the treatment of Helicobacter pylori, which can not only ensure clinical efficacy, but also reduce the use of antibiotics.
Interventions
DRUGRabeprazole
20mg bid
DRUGBismuth potassium citrate
0.6g bid
DRUGMetronidazole
0.4g qid
DRUGClarithromycin
0.5g bid
DRUGLevofloxacin
0.5g qd
Sponsors
Shanghai Zhongshan Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Participate in the trial voluntarily, fully understand the trial, and sign the informed consent form (ICF). * 18-75 years old on the day of signing the ICF. * Helicobacter pylori infection confirmed by 13C-urea breath test or rapid urease test. * Have not received Helicobacter pylori eradication treatment before. * allergic to penicillin.
Exclusion criteria
* Have received Hp eradication treatment. * Patients with severe heart, lung, kidney, liver, blood, nerve, endocrine, and psychiatric diseases. * Subjects or guardians refused to participate in the trial. * Alcohol and/or drugs Abuse (addiction or dependence) or poor compliance with doctor's judgment. * Have taken antibiotics, bismuth, proton pump inhibitors or Chinese traditional medicine 4 weeks before treatment. * Pregnant or lactating women. * Active peptic ulcer. * allergic to drugs used in the trial. * any other circumstances that are not suitable for recruitment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Eradication rate of Helicobacter pylori | At least 4 weeks after completion of therapy | Eradication of Helicobacter pylori was defined as negative result of urea breath test (\<4‰ cut-off value). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Eradication rate of Helicobacter pylori resistant strains | At least 4 weeks after completion of therapy | Eradication of Helicobacter pylori was defined as negative result of urea breath test (\<4‰ cut-off value). The antibiotic resistant strains were assessed using the E test method. |
| Eradication rate of Helicobacter pylori susceptible strains | At least 4 weeks after completion of therapy | Eradication of Helicobacter pylori was defined as negative result of urea breath test (\<4‰ cut-off value). The antibiotic susceptible strains were assessed using the E test method. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Adherence rate | 2 weeks during therapy | Adherence was defined as poor when subjects took less than 80% of the total medication. |
| Frequency of adverse events | 2 weeks during therapy | Any possible adverse events during the 14-day treatment period were recorded. |
Countries
China
Contacts
Primary ContactQi Chen, MD
Outcome results
None listed